Elypta has secured €6.1 million in a round led by Industrifonden and Sciety. The Swedish company is developing a metabolism-based liquid biopsy platform to detect and follow up on cancer. The proceeds of the seed transaction will be used for R&D. As part of the deal, Industrifonden's Jonas Jendi will join the company's board.